Mayne Pharma Group Limited
(ASX:MYX) has announced it has added specialty products to its Australian portfolio.
The pharmaceutical company has received Theraputic Goods Administration approval for Monurol granules and has recently launched Urorec capsules in Australia.
Both products are new chemical product approvals from the TGA and the first two approvals of this kind by Mayne Pharma.
CEO Scott Richards says the company was delighted about the approval from the TGA.
Shares in Mayne Pharma Group Limited
(ASX:MYX) are trading up 1.35 per cent to $0.75 cents .
